Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy

Neuroendocrinology

Volumn 97, Issue 1, 2013, Pages 74-85

  Van Vliet, Esther I ^a   Teunissen, Jaap J M ^a   Kam, Boen L R ^a   De Jong, Marion ^a   Krenning, Eric P ^a   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Gastroenteropancreatic neuroendocrine tumors; Peptide receptor radionuclide therapy; Radiolabeled somatostatin analogs; Somatostatin analogs

Indexed keywords

ANGIOPEPTIN; CHELATING AGENT; EVEROLIMUS; GALLIUM 68; LUTETIUM 177; OCTREOTHER; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; PENTETATE INDIUM; PENTETIC ACID; PENTETIC ACID OCTREOTATE[3 TYROSINE] IN; PENTETIC ACID OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN; PENTETREOTIDE IN 111; RADIOISOTOPE; RADIOSENSITIZING AGENT; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SUNITINIB; TETRAXETAN; TETRAXETAN ANGIOPEPTIN; TETRAXETAN OCTREOTATE[3 TYROSINE]; TETRAXETAN OCTREOTATE[3 TYROSINE] LU 177; TETRAXETAN OCTREOTIDE[3 TYROSINE]; TETRAXETAN OCTREOTIDE[3 TYROSINE] Y 90; TETRAXETAN OCTREOTIDE[NAPHYTHYLALANINE]; TETRAXETAN VAPREOTIDE Y; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE; YTTRIUM 90; DOTATATE LU 177; DOTATOC Y 90; RADIOPHARMACEUTICAL AGENT; RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; DOSIMETRY; DRUG BINDING; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TARGETING; GASTROENTEROPANCREATIC NEUROENDOCIRNE TUMOR; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HUMAN; IC 50; INTERMETHOD COMPARISON; ISOTOPE LABELING; KIDNEY FAILURE; LEUKEMIA; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; PANCREATIC NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; CANCER PATIENT; COMPARATIVE STUDY; RADIOACTIVITY; CARCINOMA, NEUROENDOCRINE; GASTROINTESTINAL NEOPLASMS; METABOLISM; PANCREATIC NEOPLASMS;

CARCINOMA, NEUROENDOCRINE; GASTROINTESTINAL NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE;

EID: 84874112933     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000335018     Document Type: Article

References (63)

1. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann ME: Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 1993; 54(suppl 1):72-75.
2. Janson ET, Oberg K: Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 32: 225-229.
3. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Hammel P, Rougier P: The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95:3276-3281.
4. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-4663.
5. Gabriel M, Decristoforo C, Kendler D, Do-brozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ: 68Ga-DOTA-Tyr3-octreotide PET in neuro-endocrine tumors: comparison with soma-tostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518.
6. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ: Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreo-tate) and 18F-FDG. Cancer 2008; 112: 2447-2455.
7. Reubi JC, Schar JC, Waser B, Wenger S, Hep-peler A, Schmitt JS, Macke HR: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radio-tracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273-282.
8. Valkema R, De Jong M, Bakker WH, Bree-man WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP: Phase I study of peptide receptor radionuclide therapy with [In-DTPA]oc-treotide: the Rotterdam experience. Semin Nucl Med 2002; 32:110-122.
9. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE: In-dium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32:123-132.
10. Chinol M, Bodei L, Cremonesi M, Paganelli G: Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002; 32:141-147.
11. Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, Gatti M, Chinol M, Bartolomei M, Fiorenza M, Grana C: 90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002; 66:393-398.
12. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, Caracciolo M, Macke HR, Chinol M, Paganelli G: Receptor-mediated radionuclide therapy with 90Y-DOTA-TOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003; 30:207-216.
13. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP: Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropan-creatic neuroendocrine tumors. Semin Nucl Med 2006; 36:147-156.
14. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, Bau-lieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, Kacena K A, La France N, Pauwels SA: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28:1652-1659.
15. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Macke HR, Rochlitz C, Muller-Brand J, Walter MA: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29:2416-2423.
16. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J: Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26: 1439-1447.
17. Waldherr C, Pless M, Maecke HR, Halde-mann A, Mueller-Brand J: The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuro-endocrine tumours: a clinical phase II study. Ann Oncol 2001; 12:941-945.
18. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Hal-demann A, Mueller-Brand J: Tumor response and clinical benefit in neuroendo-crine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002; 43:610-616.
19. Pfeifer AK, Gregersen T, Gronbaek H, Han-sen CP, Muller-Brand J, Herskind Bruun K, Krogh K, Kjaer A, Knigge U: Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuro-endocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocri-nology 2011; 93: 189-196.
20. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Kren-ning EP: [177Lu-DOTAOTyr3]octreotate: compa rison w ith [111In-DTPAo]oct reotide in patients. Eur J Nucl Med 2001; 28:1319-1325.
21. Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, Kwek-keboom DJ: Comparison of [(177)Lu-DOTA(0), Tyr(3)]octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006; 33:1346-1351.
22. Forrer F, Uusijarvi H, Waldherr C, Cre-monesi M, Bernhardt P, Mueller-Brand J, Maecke HR: A comparison of (111)In-DO-TATOC and (111)In-DOTATATE: biodistri-bution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31: 1257-1262.
23. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP: Treatment with the radiolabeled somatosta-tin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
24. de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, van Essen M, Kren-ning EP, Kwekkeboom DJ: Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2008; 35: 749-755.
25. Teunissen JJ, Kwekkeboom DJ, Krenning EP: Quality of life in patients with gastroen-teropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 2004; 22:2724-2729.
26. Cwikla JB, Sankowski A, Seklecka N, Bus-combe JR, Nasierowska-Guttmejer A, Jezi-orski KG, Mikolajczak R, Pawlak D, Stepien K, Walecki J: Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancre-atic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol 2010; 21: 787-794.
27. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P: In-and Y-DOTA-lan-reotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32:148-155.
28. Reubi JC, Waser B, Schaer JC, Laissue JA: So-matostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-846.
29. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC: DOTA-NOC, a high-affinity li-gand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imag ing 2003; 30: 1338-1347.
30. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, Salmon A, Glaser B, Chisin R, Mishani E, J Gross D: (68)Ga-DO-TA-NOC PET/CT imaging of neuroendo-crine tumors: comparison with (111)In-DT-PA-octreotide (OctreoScan(R)). Mol Imaging Biol 2011; 13: 583-593.
31. Wehrmann C, Senftleben S, Zachert C, Muller D, Baum R P: Results of individual patient dosimetry in peptide receptor radionu-clide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radio-pharm 2007; 22:406-416.
32. Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J: Treatment with 177Lu-DOTATOC of patients with relapse of neu-roendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005; 46: 1310-1316.
33. van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ: Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroentero-pancreatic neuroendocrine tumors. J Nucl Med 2010; 51: 383-390.
34. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP: Combination radio-nuclide therapy using 177Lu-and 90Y-la-beled somatostatin analogs. J Nucl Med 2005; 46(suppl 1):13S-17S.
35. Kunikowska J, Krolicki L, Mikolajczak R, Pawlak D, Hubalewska-Dydejczyk A, Sowa-Staszczak A, Kobylecka M: Clinical results of PRRT with 90Y-DOTATATE and 90Y/177Lu-DOTATATE-What is better for therapy? J Nucl Med 2009; 50(suppl 2):106 (abstract).
36. Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, Vellani C, Chiesa C, Martinetti A, Bogni A, Bombardieri E: Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendo-crine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging 2010; 54:84-91.
37. Kratochwil C, Giesel FL, Lopez-Benitez R, Schimpfky N, Kunze K, Eisenhut M, Kauc-zor HU, Haberkorn U: Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2010; 16: 2899-2905.
38. Pool SE, Kam B, Breeman W, Koning G, van Eijck C, Krenning E, de Jong M: Increasing intrahepatic tumor uptake of 111In-DTPA-octreotide by loco regional administration. Eur J Nucl Med Mol Imaging 2009; 36(suppl 2):S427 (abstract).
39. Limouris GS, Chatziioannou A, Kontogeor-gakos D, Mourikis D, Lyra M, Dimitriou P, Stavraka A, Gouliamos A, Vlahos L: Selective hepatic arterial infusion of In-111-DT-PA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 2008; 35: 1827-1837.
40. Kratochwil C, Giesel F, Morgenstern A, Bruchertseifer F, Mier W, Zechmann C, Apostolidis C, Haberkorn U: Regional 213Bi-DOTATOC peptide receptor alpha-therapy in patients with neuroendocrine liver metas-tases refractory to beta-radiation. J Nucl Med 2011; 52(suppl 1):29 (abstract).
41. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5: 2948-2953.
42. Rich TA, Shepard RC, Mosley ST: Four decades of continuing innovation with fluoro-uracil: current and future approaches to flu-orouracil chemoradiation therapy. J Clin Oncol 2004; 22:2214-2232.
43. Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA: A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorecta l cancer. Clin Cancer Res 2003; 9: 5842-5852.
44. van Essen M, Krenning EP, Kam BL, de Herder WW, van Aken MO, Kwekkeboom DJ: Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 743-748.
45. Claringbold PG, Brayshaw PA, Price RA, Turner JH: Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011; 38:302-311.
46. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
47. Valkema R, Pauwels SA, Kvols LK, Kwekke-boom DJ, Jamar F, de Jong M, Barone R, Wal-rand S, Kooij PP, Bakker WH, Lasher J, Kren-ning EP: Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005; 46(suppl 1):83S-91S.
48. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, Baio SM, Sanso-vini M, Paganelli G: Long-term evaluation of renal toxicity after peptide receptor radio-nuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35: 1847-1856.
49. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP: Safe and effective inhibition of renal uptake of radiolabelled octreo-tide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003; 30: 9-15.
50. van Eerd JE, Vegt E, Wetzels JF, Russel FG, Masereeuw R, Corstens FH, Oyen WJ, Boer-man OC: Gelatin-based plasma expander effectively reduces renal uptake of 111In-oc-treotide in mice and rats. J Nucl Med 2006; 47:528-533.
51. Vegt E, Wetzels JF, Russel FG, Masereeuw R, Boerman OC, van Eerd JE, Corstens FH, Oyen WJ: Renal uptake of radiolabeled oc-treotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006; 47: 432-436.
52. Rolleman EJ, Bernard BF, Breeman WA, Forrer F, de Blois E, Hoppin J, Gotthardt M, Boerman OC, Krenning EP, de Jong M: Molecular imaging of reduced renal uptake of radiolabelled [DOTA0, Tyr3]octreotate by the combination of lysine and Gelofusine in rats. Nuklearmedizin 2008; 47:110-115.
53. Melis M, Bijster M, de Visser M, Konijnen-berg MW, de Swart J, Rolleman EJ, Boerman OC, Krenning EP, de Jong M: Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging 2009; 36: 1968-1976.
54. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning E P, de Jong M: Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010; 37: 1018-1031.
55. Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, Rossi A, Bartolomei M, Mei R, Severi S, Salvatori M, Pedroli G, Paganelli G: Dosimetry for treatment with ra-diolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging 2010; 54: 37-51.
56. Kaemmerer D, Prasad V, Daffner W, Horsch D, Kloppel G, Hommann M, Baum RP: Neo-adjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 2009; 15:5867-5870.
57. Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J, Schlitt HJ: Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilob-ular hepatic metastases from a neuroendo-crine pancreatic tumor. Langenbecks Arch Surg 2010; 395: 185-192.
58. Breeman WA, Mearadji A, Capello A, Bernard BF, van Eijck CH, Krenning EP, de Jong M: Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0, Tyr3] octreotate in a rat liver micrometastases model. Int J Cancer 2003; 104: 376-379.
59. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metra-kos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-513.
60. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
61. Ginj M, Zhang H, Eisenwiener KP, Wild D, Schulz S, Rink H, Cescato R, Reubi JC, Maecke HR: New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin Cancer Res 2008; 14: 2019-2027.
62. Lewis I, Albert R, Kneuer R, Pless J, Simeon C, Kerrad S, Hoyer D, Bruns C: Medicinal chemistry of somatostatin analogs leading to the DTPA and DOTA conjugates of the multi-receptor-ligand SOM230. J Endocri-nol Invest 2005; 28:15-20.
63. Cescato R, Erchegyi J, Waser B, Piccand V, Maecke HR, Rivier JE, Reubi JC: Design and in vitro characterization of highly sst2-selec-tive somatostatin antagonists suitable for ra-diotargeting. J Med Chem 2008; 51: 4030-4037.